Dr. Reddy’s Laboratories, an India-based maker of generic pharmaceutical products, has appointed Marc Kikuchi as CEO for North American Generics in the same week the company announced a recall of mislabeled injection drugs.
The company is recalling a batch of an anticonvulsive medication, Levetiracetam, because the outside of the boxes listed different concentrations of sodium than the drug infusion bags.
“Patients who may have been administered the mislabeled product could experience adverse reactions such as somnolence, agitation, aggression, depressed level of consciousness, respiratory depression, and coma related to over dosage,” the company warns. The batch was distributed in the U.S. between August 14 and September 5, 2018.
Kikuchi joins Dr. Reddy’s from Zydus Pharmaceuticals, Inc. where he served as CEO, Americas since 2016. Prior to joining Zydus, he held leadership roles with AmerisourceBergen Corporation, Medrad Inc., PRTM, Johnson & Johnson, and Incyte Pharmaceuticals. He holds a bachelor’s degree in molecular and cell biology from the University of California at Berkeley and master of business administration from Carnegie Mellon University in strategy, marketing, and operations management.
Dr. Reddy’s Laboratories, 107 College Road East, Princeton 08540. 908-203-4900. www.drreddys.com.
